Investigation of adverse effects and healing factor properties of a novel formulation from Blue-O

The appearance of multidrug resistance of pathogens is challenging the researcher and industrial communities to develop more efficacious antimicrobial treatments. Blue-O Technology Incorporation (Blue-O Tech) has developed a novel formulation of medicine that accelerates the wound healing, while having an excellent antimicrobial strength over a broad spectrum of pathogens. The objectives of this study are to evaluate the cytotoxic effects, the immunological response, and the healing properties of this novel medicine prior to its marketing and commercialization.

Faculty Supervisor:

Dr. Horacio Bach

Student:

Joseph Chao

Partner:

Hanson Blue-O Technology INC

Discipline:

Medicine

Sector:

Pharmaceuticals

University:

University of British Columbia

Program:

Accelerate

Related projects

Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.

View all
Current openings

Find the perfect opportunity to put your academic skills and knowledge into practice!

Find Projects

Mitacs Partners

The strong support from governments across Canada, international partners, universities, colleges, companies, and community organizations has enabled Mitacs to focus on the core idea that talent and partnerships power innovation — and innovation creates a better future.

Government
Academic
Industry
Innovation

International

Load More

International

Load More

Join a thriving innovation ecosystem.

Subscribe to our newsletter now!

Subscribe
Canada